Compare Surgical Science Sweden AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 1,697 Million (Small Cap)
19.00
NA
0.00%
-0.14
2.01%
0.40
Revenue and Profits:
Net Sales:
235 Million
(Quarterly Results - Mar 2026)
Net Profit:
19 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.33%
0%
2.33%
6 Months
-1.19%
0%
-1.19%
1 Year
-78.43%
0%
-78.43%
2 Years
-75.25%
0%
-75.25%
3 Years
-86.8%
0%
-86.8%
4 Years
-79.08%
0%
-79.08%
5 Years
-79.64%
0%
-79.64%
Surgical Science Sweden AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
56.77%
EBIT Growth (5y)
44.68%
EBIT to Interest (avg)
47.45
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.14
Sales to Capital Employed (avg)
0.20
Tax Ratio
20.05%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.57%
ROE (avg)
4.01%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
0.39
EV to EBIT
7.67
EV to EBITDA
4.75
EV to Capital Employed
0.28
EV to Sales
1.05
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
3.70%
ROE (Latest)
2.01%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
235.50
268.90
-12.42%
Operating Profit (PBDIT) excl Other Income
49.80
71.00
-29.86%
Interest
1.20
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
18.60
33.30
-44.14%
Operating Profit Margin (Excl OI)
125.80%
174.80%
-4.90%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -12.42% vs 2.01% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -44.14% vs 63.24% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
992.30
884.10
12.24%
Operating Profit (PBDIT) excl Other Income
192.30
209.90
-8.38%
Interest
6.30
5.70
10.53%
Exceptional Items
0.00
-0.30
100.00%
Consolidate Net Profit
66.80
131.60
-49.24%
Operating Profit Margin (Excl OI)
109.80%
169.00%
-5.92%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 12.24% vs 0.14% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -49.24% vs -43.76% in Dec 2024
About Surgical Science Sweden AB 
Surgical Science Sweden AB
Pharmaceuticals & Biotechnology
Surgical Science Sweden AB is a Sweden-based company, which provides with virtual reality simulators for evidence based laparoscopic and endoscopic training. The systems comprise LapSim, EndoSim and TeamSim trainings. Each training combine graphics and cognitive instruction, imply navigation on touch screens and feature tactile feedback technology. The LapSim trainings consist of laparoscopic exercises that range from basic navigation to advanced suturing, the EndoSim endoscopic exercises range from functions of the scope handle and tube, to loop reduction. The TeamSim comprises procedure modules to train in a real world operation room environment and helps to build team communication skills in crisis and routine situations. The training systems are used by medical training centers and institutes worldwide for practice, validation and certification of students, surgeons, and medical doctors.
Company Coordinates 
Company Details
Drakegatan 7 A, 3 tr. , GOETEBORG None : 412 50
Registrar Details






